HRS-4729 vs retatrutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HRS-4729
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06762600 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: March 2027 · NCT07690826 (registry estimate)
Reported efficacy
Adverse events (AEs) (Screening period up to day 43.): In the multiple-dose portion at Week 12, participants receiving multiple doses of 12 mg HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo. HRS-4729 demonstrated linear pharmacokinetics with a half-life of approximately 4 to 5 days, supporting once-weekly dosing, and safety and tolerability consistent with GLP-1-based treatments. (not_applicable)
Result source: NCT06762600
retatrutide
Developed by Eli Lilly
NCT05882045 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)
Result source: NCT05929079
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRS-4729 | retatrutide |
|---|---|---|
| Body weight, % change | —Not reported | -17.4% vs -1.6%−15.8 vs placeboNCT0488176014 other results
|
| Weight loss of 5% or more | —Not reported | 100% vs 27%+73 vs placeboNCT0488176011 other results
|
| Weight loss of 10% or more | —Not reported | 93% vs 9%+84 vs placeboNCT0488176011 other results
|
| Waist circumference, change (cm) | —Not reported | -19.6 vs -2.6−17 vs placeboNCT0488176011 other results
|
Body weight, % change
- HRS-4729
- —Not reported
- retatrutide
- -17.4% vs -1.6%−15.8 vs placeboNCT04881760
14 other results
- -16.6% vs -1.6% NCT04881760
- -18.3% vs -1.6% NCT04881760
- -12% vs -1.6% NCT04881760
- -13.8% vs -1.6% NCT04881760
- -7.2% vs -1.6% NCT04881760
- -24.2% vs -2.1% NCT04881760
- -21.7% vs -2.1% NCT04881760
- -23.9% vs -2.1% NCT04881760
- -16.3% vs -2.1% NCT04881760
- -17.8% vs -2.1% NCT04881760
- -8.7% vs -2.1% NCT04881760
- -20.8% vs -4% NCT05929079
- -19.1% vs -4% NCT05929079
- -12.7% vs -4% NCT05929079
Weight loss of 5% or more
- HRS-4729
- —Not reported
- retatrutide
- 100% vs 27%+73 vs placeboNCT04881760
11 other results
- 97% vs 26% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 26% NCT04881760
- 100% vs 26% NCT04881760
- 87% vs 27% NCT04881760
- 97% vs 27% NCT04881760
- 87% vs 26% NCT04881760
- 94% vs 26% NCT04881760
- 64% vs 27% NCT04881760
- 59% vs 26% NCT04881760
Weight loss of 10% or more
- HRS-4729
- —Not reported
- retatrutide
- 93% vs 9%+84 vs placeboNCT04881760
11 other results
- 90% vs 3% NCT04881760
- 90% vs 9% NCT04881760
- 91% vs 9% NCT04881760
- 83% vs 3% NCT04881760
- 94% vs 3% NCT04881760
- 73% vs 9% NCT04881760
- 76% vs 9% NCT04881760
- 59% vs 3% NCT04881760
- 72% vs 3% NCT04881760
- 27% vs 9% NCT04881760
- 25% vs 3% NCT04881760
Waist circumference, change (cm)
- HRS-4729
- —Not reported
- retatrutide
- -19.6 vs -2.6−17 vs placeboNCT04881760
11 other results
- -14.3 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -13.7 vs -2.6 NCT04881760
- -15.0 vs -2.6 NCT04881760
- -14.6 vs -2.6 NCT04881760
- -14.9 vs -2.6 NCT04881760
- -10.3 vs -2.6 NCT04881760
- -12.6 vs -2.6 NCT04881760
- -6.5 vs -2.6 NCT04881760
- -5.4 vs -2.6 NCT04881760
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-4729: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HRS-4729: 0 of 4 rows · retatrutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | retatrutide |
|---|---|
| Dropout rate | 12.9%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results14.3%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 17.1%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 23.5%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 21.2%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 13%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Discontinued due to AEs | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 2.9%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 3%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1.4%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Serious AEs | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 5.7%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 6.1%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4.3%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Most frequent reported AEs | 12 mg (2 mg) nausea 45.2% (placebo 11.4%) decreased appetite 29% (placebo 8.6%) covid-19 24.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results8 mg (2 mg) diarrhoea 20% (placebo 11.4%) covid-19 17.1% (placebo 20%) nausea 17.1% (placebo 11.4%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 8 mg (4 mg) nausea 60% (placebo 11.4%) covid-19 31.4% (placebo 20%) decreased appetite 31.4% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg nausea 36.4% (placebo 11.4%) decreased appetite 24.2% (placebo 8.6%) covid-19 18.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg (2 mg) decreased appetite 18.2% (placebo 8.6%) nausea 18.2% (placebo 11.4%) constipation 15.2% (placebo 2.9%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1 mg covid-19 18.8% (placebo 20%) nausea 14.5% (placebo 11.4%) decreased appetite 13% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
retatrutide
show 14 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-4729's landscape · retatrutide's landscape